Suggested remit - To appraise the clinical and cost effectiveness of ponesimod within its marketing authorisation for treating relapsing forms of multiple sclerosis.
 
Status In progress
Process STA 2018
ID number 1393

Provisional Schedule

Committee meeting: 1 09 September 2021
Expected publication 17 November 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Peninsula Technology Assessment Group (PenTAG), University of Exeter

Consultees

Companies sponsors Janssen (ponesimod)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Multiple Sclerosis Society
  Multiple Sclerosis Trust
Professional groups Royal College of Physicians
  UK Multiple Sclerosis Specialist Nurse Association

Commentators

Assessment group None
Comparator companies Biogen Idec (dimethyl fumarate, interferon beta-1a, natalizumab, peginterferon beta-1a)
  Genzyme Therapeutics (alemtuzumab, teriflunomide)
  Merck (cladribine tablets, interferon beta-1a)
  Novartis (fingolimod, interferon beta-1b, siponimod, ofatumumab)
  Teva UK (glatiramer acetate)
  Roche (ocrelizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
12 January 2021 Invitation to participate
05 October 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of ponesimod for treating relapsing multiple sclerosis. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late October 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
05 October 2020 In progress. Topic is in progress
17 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
19 November 2019 - 17 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance